NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $578,000 | +5.7% | 31,865 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $547,000 | -13.6% | 31,865 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $633,000 | +19.4% | 31,865 | +2.2% | 0.00% | 0.0% |
| Q4 2020 | $530,000 | +10.9% | 31,180 | +9.3% | 0.00% | 0.0% |
| Q3 2020 | $478,000 | -63.1% | 28,517 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $1,294,000 | +156.7% | 57,034 | +100.2% | 0.00% | 0.0% |
| Q1 2020 | $504,000 | -16.7% | 28,485 | -0.5% | 0.00% | 0.0% |
| Q4 2019 | $605,000 | -6.3% | 28,625 | -19.2% | 0.00% | 0.0% |
| Q3 2019 | $646,000 | -48.7% | 35,411 | 0.0% | 0.00% | -66.7% |
| Q2 2019 | $1,260,000 | +29.8% | 35,411 | +22.7% | 0.00% | +50.0% |
| Q1 2019 | $971,000 | +32.1% | 28,862 | +29.3% | 0.00% | +100.0% |
| Q4 2018 | $735,000 | -18.9% | 22,320 | +50.0% | 0.00% | 0.0% |
| Q3 2018 | $906,000 | +155.2% | 14,880 | +104.5% | 0.00% | 0.0% |
| Q2 2018 | $355,000 | +105.2% | 7,276 | +346.1% | 0.00% | – |
| Q1 2018 | $173,000 | – | 1,631 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |